insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
Published 2 months ago • 61 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
1:56
positive results for acalabrutinib in waldenström's macroglobulinemia
-
1:30
bendamustine-rituximab vs ibrutinib as frontline therapy in waldenström's macroglobulinemia
-
1:09
ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
-
2:14
single agent ibrutinib produces long-term disease control in waldenström’s: the pivotal trial
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
3:03
long-term follow-up of ibrutinib in waldenström's macroglobulinemia
-
2:23
waldenström’s: predicting ibrutinib responses
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
7:37
living with waldenstrom's with bob rupert
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
2:04
venetoclax and ibrutinib: the future for treating wm
-
2:04
ibrutinib monotherapy in wm: long-term follow-up data
-
2:12
the optimal sequencing of therapies in waldenström’s macroglobulinemia
-
1:53
bringing ibrutinib to the frontline of chronic gvhd treatment
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia
-
1:35
phase i/ii bruin update: efficacy of pirtobrutinib in r/r waldenström's macroglobulinemia
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia